Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

China to Re-Start IPO Process

publication date: Nov 10, 2015
After a four-month suspension, China will once again allow IPOs, the government announced after the close of trading last week. The halt in initial offerings was meant to stop the June-July decline in China stock prices by preventing investors from selling old holdings to buy new ones. The decline did stop -- in August -- and now market indexes are up 12% since the beginning of 2015. There were 28 companies queued to IPO at the time of the halt. All of them may debut before the end of the year. Initially, ten companies will IPO, including at least one pharma company: Jiangxi Fushine Pharma. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital